Assessment · Essay 02
Objective ADHD testing, explained without the sales pitch
Yes, objective tools exist. Yes, some are FDA-cleared and genuinely useful. No, none of them can diagnose your child — and understanding why tells you exactly what they're for.
The landscape in one table
| Tool | What it measures | Status | Honest read |
|---|---|---|---|
| QbTest / QbCheck (Qbtech) | 15–20 min computer attention task + motion tracking (infrared camera in-clinic; webcam remotely), scored against age- and sex-matched norms | FDA-cleared as an aid to diagnosis and treatment evaluation, ages 6–60; recommended by NICE as an adjunct for ages 6–17 | The best-validated objective aid available. Adds data; does not decide. |
| Standard CPTs (Conners CPT-3, TOVA) | Sustained attention and impulsivity on a repetitive computer task | Long-established psychological instruments | Useful within full neuropsychological testing; weak as standalone screens. |
| EEG theta/beta (NEBA) | Brainwave ratio associated with ADHD at group level | FDA-authorized in 2013 | Reliability proved limited at the individual level; rarely used in practice today. |
| VR classroom tasks | Attention while simulated distractions occur | Research stage | Promising ecological validity in pediatric studies; not yet standard of care. |
| Machine learning models | Pattern analysis across scales, tasks, and signals | Research stage | Impressive numbers in papers; no independent clinical validation yet. |
What the best evidence actually showed
The strongest trial in this space is the AQUA randomized controlled trial: when clinicians assessing children had QbTest reports available, they reached diagnostic decisions substantially faster — with no measurable loss of accuracy — and excluded ADHD more confidently when it wasn't present. Read that carefully: the demonstrated benefit is a faster, more confident clinical process, not a machine that outperforms clinicians.
That's also exactly why regulators cleared these tools as aids. A 20-minute task in a quiet room measures a slice of attention and movement. It cannot see the thing the diagnosis actually requires: impairment across settings, over months, in a child's real life.
When objective testing earns its cost
- Ambiguous pictures — home and school reports disagree, or scales sit near thresholds.
- High-stakes skepticism — a parent (or teen) who doubts the diagnosis and deserves more than "trust me."
- Treatment verification — repeating the test on medication provides a before/after that rating scales alone can't match.
- Countering bias — norm-referenced data doesn't know your child's birthday or gender, which blunts the referral biases covered in Essay 01.
Typical cash cost runs a few hundred dollars per administration — modest against the cost of years of imprecisely aimed treatment.
Sources
- Hollis C et al., AQUA randomised controlled trial, J Child Psychol Psychiatry 2018. E1 · RCT
- NICE health technology evaluation of QbTest for children and young people. E1 · Guideline
- FDA 510(k) clearances, QbTest and QbCheck (K190726). E2 · Regulatory
- FDA De Novo authorization, NEBA EEG system, 2013. E2 · Regulatory